ULORIC- febuxostat tablet

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

유효 성분:

febuxostat (UNII: 101V0R1N2E) (febuxostat - UNII:101V0R1N2E)

제공처:

Takeda Pharmaceuticals America, Inc.

INN (국제 이름):

febuxostat

구성:

febuxostat 40 mg

관리 경로:

ORAL

처방전 유형:

PRESCRIPTION DRUG

치료 징후:

ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. Limitations of Use : ULORIC is not recommended for the treatment of asymptomatic hyperuricemia. ULORIC is contraindicated in patients being treated with azathioprine or mercaptopurine [see Drug Interactions (7)] . Risk Summary Limited available data with ULORIC use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. No adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (MRHD). No adverse developmental effects were observed in

제품 요약:

ULORIC 40 mg tablets are light green to green in color, round, debossed with "TAP" on one side and "40" on the other side and supplied as: ULORIC 80 mg tablets are light green to green in color, teardrop shaped, debossed with "TAP" on one side and "80" on the other side and supplied as: Protect from light. Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].

승인 상태:

New Drug Application

환자 정보 전단

Takeda Pharmaceuticals America, Inc.
----------
This Medication Guide has been approved by the U.S.
Food and Drug Administration
ULR015 R9
Revised: February
2019
MEDICATION GUIDE
ULORIC (Ū–'lor–ik)
(febuxostat)
tablets, for oral use
Read the Medication Guide that comes with ULORIC before you start
taking it and each time you get a
refill. There may be new information. The Medication Guide does not
take the place of talking with your
doctor about your medical condition or your treatment.
What is the most important information that I should know about
ULORIC?
ULORIC may cause serious side effects, including:
Heart -related deaths.
Call your doctor or get emergency medical help right away if you have
any of the following symptoms,
especially if they are new, worse, or worry you:
•
chest pain
•
shortness of breath or trouble breathing
•
dizziness, fainting or feeling lightheaded
•
rapid or irregular heartbeat
•
numbness or weakness on one side of your
body
•
slurring of speech
•
sudden blurry vision or sudden severe
headache
What is ULORIC?
ULORIC is a prescription medicine called a xanthine oxidase (XO)
inhibitor used to lower blood uric acid
levels in adult patients with gout when allopurinol has not worked
well enough or when allopurinol is not
right for you.
ULORIC is not for use in people who do not have symptoms of high blood
uric acid levels.
It is not known if ULORIC is safe and effective in children.
Who should not take ULORIC?
Do not take ULORIC if you:
•
take azathioprine (Azasan, Imuran)
•
take mercaptopurine (Purinethol, Purixan)
What should I tell my doctor before taking ULORIC?
Before taking ULORIC tell your doctor about all of your medical
conditions, including if you:
•
have taken allopurinol and what happened to you while you were taking
it.
•
have a history of heart disease or stroke.
•
have liver or kidney problems.
•
are pregnant or plan to become pregnant. It is not known if ULORIC
will harm your unborn baby.
Talk with your doctor if you are pregnant or plan to bec

제품 특성 요약

ULORIC- FEBUXOSTAT TABLET
TAKEDA PHARMACEUTICALS AMERICA, INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
ULORIC SAFELY AND
EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ULORIC.
ULORIC (FEBUXOSTAT) TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 2009
WARNING: CARDIOVASCULAR DEATH
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
GOUT PATIENTS WITH ESTABLISHED CARDIOVASCULAR (CV) DISEASE TREATED
WITH ULORIC HAD
A HIGHER RATE OF CV DEATH COMPARED TO THOSE TREATED WITH ALLOPURINOL
IN A CV
OUTCOMES STUDY. (5.1)
CONSIDER THE RISKS AND BENEFITS OF ULORIC WHEN DECIDING TO PRESCRIBE
OR CONTINUE
PATIENTS ON ULORIC. ULORIC SHOULD ONLY BE USED IN PATIENTS WHO HAVE AN
INADEQUATE
RESPONSE TO A MAXIMALLY TITRATED DOSE OF ALLOPURINOL, WHO ARE
INTOLERANT TO
ALLOPURINOL, OR FOR WHOM TREATMENT WITH ALLOPURINOL IS NOT ADVISABLE.
(1)
INDICATIONS AND USAGE
ULORIC is a xanthine oxidase (XO) inhibitor indicated for the chronic
management of hyperuricemia in
adult patients with gout who have an inadequate response to a
maximally titrated dose of allopurinol, who
are intolerant to allopurinol, or for whom treatment with allopurinol
is not advisable. (1)
Limitations of Use:
ULORIC is not recommended for the treatment of asymptomatic
hyperuricemia. (1)
DOSAGE AND ADMINISTRATION
Recommended dosage is 40 mg or 80 mg once daily. The recommended
starting dosage is 40 mg
once daily. For patients who do not achieve a serum uric acid (sUA)
less than 6 mg/dL after 2 weeks,
the recommended dosage is 80 mg once daily. (2.1)
Patients with severe renal impairment: Limit the dosage to 40 mg once
daily. (2.2, 8.6)
Flare prophylaxis is recommended upon initiation of ULORIC. (2.4)
Can be administered without regard to food or antacid use. (2.1)
DOSAGE FORMS AND STRENGTHS
Tablet: 40 mg, 80 mg. (3)
CONTRAINDICATIONS
ULORIC is contraindicated in patients being treated with azathioprine
or mercaptopurine. (4)
WARNINGS AND PRECAUTIONS
Gout Flares: An increase in gout flares i